NCT02096341View on ClinicalTrials.gov

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Malignant Solid TumorLymphomas

Interventions

DRUG

RRx-001

"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"

Trial Locations (1)

37203

Sarah Cannon Research Institute, Nashville

Sponsors

Lead Sponsor

EpicentRx, Inc.

All Listed Sponsors

lead

EpicentRx, Inc.

INDUSTRY